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Abstract
Desmoid-type fibromatosis (DF), also known as aggressive fibromatosis, is a locally aggressive benign fibroblastic neoplasm 
that can infiltrate or recur but cannot metastasize. It is rare, with an estimated annual incidence of two to four new cases per 
million people. Most DFs occur sporadically, but it may also be associated with the hereditary syndrome familial adeno-
matous polyposis. Treatment is necessary when the disease is symptomatic, especially in case of compression of critical 
structures. When possible, surgical resection is the treatment of choice; however, recurrence is common. Due to the high rate 
of recurrence, imaging plays an important role not only in diagnosis, but also in the management of DF. Although there are a 
number of studies describing CT and MRI findings of DF, there is no description of contrast-enhanced ultrasound findings.
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Sommario
La fibromatosi di tipo desmoide (DF), anche conosciuta col nome di fibromatosi aggressiva, è una neoformazione benigna 
localmente aggressiva con la capacità di infiltrare o recidivare ma incapace di metastatizzare. È rara con un’incidenza annua- 
le stimata di 2-4 nuovi casi per milione, costituendo approssimativamente lo 0.03% di tutte le neoplasie e meno del 3% dei 
tumori dei tessuti molli. La maggior parte delle DF sono sporadiche ma possono anche essere associate con la sindrome della 
poliposi familiare (FAP). Il trattamento è necessario quando la malattia è sintomatica, specialmente in caso di compressione 
di strutture critiche. Quando possibile, la resezione chirurgica è il trattamento di scelta, sebbene la recidiva sia comune. Visto 
l’elevato tasso di ricadute, l’imaging gioca un ruolo importante non solo nella diagnosi ma anche nella gestione della DF. 
Sebbene vi siano un certo numero di studi che descrivono le caratteristiche della DF in TC e RMN, non c’è alcun lavoro che 
descriva la patologia nell’ecografia con mezzo di contrasto (CEUS).
Introduction
Desmoid-type fibromatosis (DF), also known as aggressive 
fibromatosis, is a locally aggressive benign fibroblastic neo-
plasm that can infiltrate or recur but cannot metastasize. DF 
can arise anywhere in the body. It is rare, with an estimated 
annual incidence of two to four new cases per million peo-
ple, accounting for approximately 0.03% of all neoplasms 
and less than 3% of all soft tissue tumors [1, 2]. Most DFs 
occur sporadically, but it may also be associated with the 
hereditary syndrome familial adenomatous polyposis (FAP). 
The combination of FAP and DF is known as Gardner’s 
syndrome [3]. DF is classified, based on the location, as 
either extra-abdominal or intra-abdominal. Intra-abdominal 
DF may occur sporadically when associated with FAP as 
Gardner’s syndrome; it typically manifests as slow-growing 
masses and may present with a series of complications, 
including intestinal obstruction and bowel ischemia.
Treatment is necessary when the disease is symptomatic, 
especially in the case of compression of critical structures. 
When possible, surgical resection is the treatment of choice 
[4]; however, recurrence is common (19–77%) [5, 6]. Non-
surgical treatment options include radiation (as an adjuvant 
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treatment to reduce the risk of local recurrence) and sys-
temic therapy (cytotoxic agents, molecular-targeted agents 
and anti-estrogen therapy).
Due to the high rate of recurrence, imaging plays an 
important role not only in diagnosis, but also in the manage-
ment of DF. Although there are a number of studies describ-
ing CT and MRI findings of DF [7–13], there is no descrip-
tion of contrast-enhanced ultrasound (CEUS) findings.
Case description
A 66-year-old woman was admitted to the emergency depart-
ment of our hospital for abdominal pain in the left flank. 
The patient described accidental trauma 10 days before and 
worsening pain over the last 3 days. A FAST examination 
showed no peritoneal fluid, and an abdominal X-ray showed 
subocclusion. Contrast-enhanced CT was performed, show-
ing a large, poorly enhanced mass in the left abdomen, sug-
gesting an intestinal tumor (Fig. 1a, b). A similar situation 
was observed using MRI after injecting gadolinium contrast 
agent (Fig. 2a, b). The patient’s condition deteriorated dur-
ing the night and the surgeon requested an ultrasound (US) 
examination. The US showed a predominantly solid hypo-
echoic mass with a cystic portion and poor color Doppler 
signal (Fig. 3a, b). Contrast-enhanced US (CEUS) was per-
formed using a low mechanical index (MI) (range 0.04–0.1) 
after the administration of SonoVue (Bracco™). SonoVue 
is a blood pool US contrast agent consisting of microbub-
bles. A total of 4.8 ml was administered in two intravenous 
bolus doses of 2.4 ml. The second dose was injected 15 min 
after the first, and both were followed by a 5-ml saline flush 
[14]. The CEUS showed hyper-enhancement in the arterial 
phase with later washout after 110 s. The contrast agent also 
showed persistence in the late phase after 3 min (Fig. 4a, b). 
The patient underwent video-assisted laparoscopy and the 
final diagnosis was DF (Fig. 5a–d).
Discussion
DF is an uncommon disease that is benign, but aggressive 
due to its local infiltration capacity. The disease originates 
from an irregular proliferation of well-differentiated fibro-
blasts resulting from the abnormal healing of previous tis-
sue damage. Onset is associated with hormonal factors, 
genetic predisposition and atypical connective tissue syn-
thesis [15, 16]. The highest incidence is recorded in young 
adults (20–40 years), with no difference between genders 
Fig. 1  a, b Contrast-enhanced 
CT: A venous phase; B late 
phase. Early enhancement of the 
mass and persistent enhance-
ment within the mass in the late 
phase
Fig. 2  a, b Contrast-enhanced 
MRI: A venous phase; B late 
phase. Early enhancement of the 
mass and persistent enhance-
ment within the mass in the late 
phase
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Fig. 3  a, b US: A grayscale; B 
US color Doppler shows a solid 
mass with a liquid area. Color 
Doppler shows the presence of 
vessels within the mass
Fig. 4  a, b CEUS: A venous 
phase; B late phase. Enhance-
ment during the venous phase 
(110 s) and presence of contrast 
agent in the late phase (210 s)
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[15]. The clinical features of DF depend on the localiza-
tion of the lesion, since this neoplasm is usually asympto-
matic until it compresses or infiltrates nearby structures.
In the described case, the patient experienced acciden-
tal trauma 10 days before admission. Trauma has been 
reported to have a role in triggering the proliferation of 
a neoplastic mass [17–19]. This is probably true, but it 
cannot explain our case, since the time interval between 
the trauma and the onset of symptoms was too short. It 
is more likely that the neoplastic mass had been growing 
slowly over a long period of time and that the clinical signs 
resulted from the trauma.
All diagnostic images were performed immediately after 
hospital admission. The CT scan and MRI suggested a diag-
nosis of intestinal tumor.
The US and CEUS examinations were performed in 
emergency.
CEUS has previously been proven effective for several 
organs [20–24]. However, to the best of our knowledge, this 
is the first report of the use of CEUS in the diagnosis of 
DF. The good temporal resolution of CEUS allows the best 
assessment of enhancement and washout times. Very early 
enhancement is characteristic of a benign mass, meaning 
a vascularization from the peripheral vessel, while later 
Fig. 5  a–d Histological examination showing: A panoramic view of 
the bowel wall with extramural fibroproliferative process (hematoxy-
lin–eosin); B infiltration of the perivisceral adipose tissue (magnifica-
tion ×50, hematoxylin/eosin); C details showing low-grade fusocellu-
lar proliferation and delicately fibrillated cytoplasm; the karyokinetic 
process is insignificant. There is characteristic leakage of erythro-
cytes (magnification ×200, hematoxylin/eosin); D strongly positive 
for β-catenin (magnification ×200)
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enhancements could indicate different mesenchymal ori-
gins. Washout times could also be meaningful. In a recent 
study, early washout (/120 s) was found to be characteris-
tic of malignant tumors [9]. Using CEUS, we were able to 
depict a well-vascularized tumor, with late wash-in and early 
washout, all of which suggested a malignant tumor [9, 10]. 
In our case, after early enhancement of the contrast agent, 
we relieved the very long washout: a typical aspect of benign 
lesions probably due to the presence of fibrotic tissue.
CEUS can depict very well vascular patterns and the rela-
tion to adjacent major blood vessels. However, the general 
principles of CEUS examination may be applicable to DF, 
thus making the diagnosis more accurate.
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